Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients

Breast Journal

Volumn 21, Issue 2, 2015, Pages 155-160

  Mego, Michal ^a,b   Karaba, Marian ^b   Minarik, Gabriel ^a   Benca, Juraj ^b   Sedlácková, Tatiana ^a   Tothova, Lubomira ^a   Vlkova, Barbora ^a   Cierna, Zuzana ^a   Janega, Pavol ^a,c   Luha, Jan ^a   Gronesova, Paulina ^d   Pindak, Daniel ^b,e   Fridrichova, Ivana ^d   Celec, Peter ^a   Reuben, James M ^f   Cristofanilli, Massimo ^g   Mardiak, Jozef ^a,b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c Institute of Normal and Pathological Physiology   (Slovakia)

^d CANCER RESEARCH INSTITUTE   (Slovakia)

^e SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^f UNIVERSITY OF TEXAS   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

breast cancer; circulating tumor cells; venous tromboembolism

Indexed keywords

TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL1; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UROKINASE; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLASMA; PRIMARY TUMOR; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VENOUS THROMBOEMBOLISM; BLOOD; BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BLOOD COAGULATION; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VENOUS THROMBOEMBOLISM;

EID: 84924227747     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12388     Document Type: Article

References (15)

1. Silverstein MD, Heit JA, Mohr DN, et al,. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
2. Chew HK, Wun T, Harvey DJ, et al,. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007; 25: 70-6.
3. Cristofanilli M, Budd GT, Ellis MJ, et al,. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
4. Lucci A, Hall CS, Lodhi AK, et al,. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13: 688-95.
5. Mego M, Mani SA, Cristofanilli M,. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol 2010; 7: 693-701.
6. Mego M, De Giorgi U, Broglio K, et al,. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer 2009; 101: 1813-6.
7. Kirwan CC, McDowell G, McCollum CN, et al,. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008; 99: 1000-6.
8. Dass K, Ahmad A, Azmi AS, et al,. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-36.
9. Kajabova V, Smolkova B, Zmetakova I, et al,. RASSF1A promoter methylation levels positively correlate with estrogen receptor expression in breast cancer patients. Transl Oncol 2013; 6: 297-304.
10. Mego M, Mani SA, Lee BN, et al,. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 2012; 130: 808-16.
11. Cierna Z, Mego M, Janega P, et al,. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer 2014; 14: 472.
12. Remmele W, Schicketanz KM,. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) versus subjective grading (IRS). Pathol Res Pract 1993; 189: 862-6.
13. Kwaan HC, Mazar AP, McMahon BJ,. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2013; 39: 382-91.
14. Meng S, Tripathy D, Shete S, et al,. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A 2006; 103: 17361-5.
15. Tögel F, Datta C, Badbaran A, et al,. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. J Hematother Stem Cell Res 2001; 10: 141-5.